Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267546 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2NPSR1PHGDHCCR5SLC6A2 | |
| SCHEMBL31334420 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2SLC6A2SLC6A4POLBALDH1A1 | |
| SCHEMBL23425968 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2NPSR1PHGDHPAOXCCR5 | |
| SCHEMBL1990941 | 0.82 | CYP2D6 (0.33) | SMN1; SMN2SLC6A2SLC6A4POLBALDH1A1 | |
| SCHEMBL3295637 | 0.82 | CYP2D6 (0.33) | SMN1; SMN2SLC6A2SLC6A4ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3301867 | 0.80 | CYP2D6 (0.33) | SLC6A2SLC6A4ALDH1A1TSHR | |
| SCHEMBL23089543 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2NPSR1SLC6A2SLC6A4TSHR | |
| SCHEMBL18717637 | 0.78 | MEN1 (0.31) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23269701 | 0.77 | NPSR1 (0.45) | SMN1; SMN2NPSR1SLC6A2SLC6A4POLB | |
| SCHEMBL16565596 | 0.77 | CXCR4 (0.33) | SLC6A2SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-114945366-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885NPSR1 2913/4885PHGDH 620/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885NPSR1 2913/4885PHGDH 620/4885 |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SMN1; SMN2 4510/4885NPSR1 83/4885PHGDH 3753/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SMN1; SMN2 4544/4885NPSR1 80/4885PHGDH 3807/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885NPSR1 2913/4885PHGDH 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.